

August 16, 2024
Sawai Pharmaceutical Co., Ltd.

Sawai Receives Approvals for Six Generic Drugs with 11 Strengths

Osaka, Japan – August 15, 2024 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Motohiko Kimura) received approvals by the Ministry of Health, Labour and Welfare for Six generic drugs with 11 strengths. The four compounds marked with an asterisk below are approved for the first time as generics**.

**Ezerosu[®] Combination Tablets are Ezetimibe and Rosuvastatin Calcium, and are counted as one compound.

The list of approved products:

1. Rivaroxaban Tablets, OD Tablets

Generic name:	Rivaroxaban	Strengths:	Tablets, OD Tablets: 10mg, 15mg
Brand products:	Xarelto [®] tablets, OD tablets 10mg, 15mg		

2. Vildagliptin Tablets

Generic name:	Vildagliptin*	Strengths:	Tablets: 50mg
Brand products:	Equa [®] Tablets 50mg		

3. Saxagliptin Tablets

Generic name:	Saxagliptin Hydrate*	Strengths:	Tablets: 2.5mg, 5mg
Brand products:	ONGLYZA [®] Tablets 2.5mg, 5mg		

4. Ezerosu[®] Combination Tablets

Generic name:	Ezetimibe, Rosuvastatin Calcium*	Strengths:	Combination Tablets: LD, HD
Brand products:	ROSUZET [®] Combination Tablets LD, HD		

5. Hydroxychloroquine Sulfate Tablets

Generic name:	Hydroxychloroquine Sulfate*	Strengths:	Tablets: 200mg
Brand products:	Plaquenil [®] Tablets 200mg		

6. Fingolimod Capsules

Generic name:	Fingolimod Hydrochloride	Strengths:	Capsules: 0.5mg
Brand products:	IMUSERA [®] Capsules 0.5mg, GILENYA [®] Capsules 0.5mg		

The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.



Corporate Communications, Sawai Pharmaceutical Co., Ltd.

E-mail : koho@sawai.co.jp